Vagus Nerve Stimulation Produces Durable Improvements in Severe Treatment-Resistant Depression, RECOVER Trial Shows
核心洞察
The RECOVER trial enrolled 493 patients with severe treatment-resistant depression (搜索) who had failed an average of 13 prior treatments and lived with depression for a mean of 29 years.
At 12 months, 69% of patients receiving active VNS showed meaningful improvement, and over 80% of responders maintained or improved their benefits at 24 months.
Among patients with the strongest 12-month response (≥50% symptom reduction), 92% were still showing benefit at two years, with one in five patients effectively free of depressive symptoms.
A major US clinical trial has demonstrated that vagus nerve stimulation (搜索) (VNS) can produce long-lasting improvements in patients with the most severe, treatment-resistant forms of depression, with benefits that persist and even deepen over two years.
The findings, published in the International Journal of Neuropsychopharmacology, come from the RECOVER trial, which enrolled 493 people across the United States. All participants had failed at least four treatment attempts for their current depressive episode, but the reality was far more dire: on average, each patient had already tried 13 treatments that failed to help them before enrolling.
"They had spent more than half of their lives sick with depression," said psychiatry researcher Charles Conway from Washington University in St. Louis, who led the study. The average participant had lived with depression for 29 years, and three-quarters were unable to work.
"We believe the sample in this trial represents the sickest treatment-resistant depressed patient sample ever studied in a clinical trial," Conway said.
How Vagus Nerve Stimulation (搜索) Works
The vagus nerve is one of the longest nerves in the body, running from the brainstem through the neck and chest down to the abdomen, connecting the brain to the heart, lungs, and digestive system. VNS therapy involves surgically implanting a small device — similar in size to a pacemaker — under the skin of the chest. A thin wire connects it to the left vagus nerve in the neck, and the device delivers brief, low-level electrical pulses at regular intervals.
The US FDA approved VNS for treatment-resistant depression (搜索) in 2005, though exactly how it exerts its antidepressant effects is not fully understood.
Trial Design and Key Findings
In the RECOVER trial, all participants had VNS devices implanted, but for the first 12 months, only half of the devices were switched on; the other half served as the control group. The latest report focuses on outcomes in the 214 patients who received active VNS from the beginning, tracking whether improvements held through the second year.
The results were striking. About 69% of patients had a meaningful improvement on at least one measure after 12 months. Among those responders, more than 80% maintained or improved their benefits at 24 months across measures of depressive symptoms, quality of life, and daily functioning.
For patients who experienced the strongest response at 12 months — defined as a 50% or greater reduction in symptoms — 92% were typically still showing benefit two years in.
"We were shocked that one in five patients was effectively without depressive symptoms at the end of two years," Conway said. "These results are highly atypical, as most studies of markedly treatment-resistant depression (搜索) have very poor sustainability of benefit, certainly not at two years."
Delayed-Onset Benefits
One of the most encouraging findings involved patients who did not benefit from VNS in the first year. Roughly one-third of those who showed no meaningful benefit at 12 months went on to improve by 24 months, suggesting that VNS may take considerable time to show effects in some individuals but can eventually help.
"With this kind of chronic, disabling illness, even a partial response to treatment is life-altering," Conway said. "And with vagus nerve stimulation (搜索) we're seeing that benefit is lasting."
Limitations and Next Steps
The trial was funded by LivaNova, the company that manufactures the VNS device, which has a financial interest in the trial's outcome. The data are intended to inform a coverage decision by the US Centers for Medicare and Medicaid Services, which currently does not cover the therapy.
Depression affects more than 300 million people worldwide, and up to a third do not respond to standard treatments. For those patients, VNS may offer a path forward — not as a rapid fix, but as a durable intervention that can reshape the trajectory of even the most intractable depression.
"Seeing results like that for this complicated illness makes me optimistic about the future of this treatment," Conway said.